Quantcast

Latest localized prostate cancer Stories

2008-10-03 09:00:38

LYON, France, Oct. 3, 2008 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its Ablatherm-HIFU and next generation Sonolith I-Sys devices were highlighted at two major European urological conferences: the 60th Annual Congress of the German Society of Urology (DGU) from September 24-27 and the Italian Society of Urology (SIU) from September 22-28. Both congresses showcased EDAP's focus on increasing physician adoption of...

2008-09-30 03:00:00

By Strief, Dawn Mielke This review of the state of the science for prostate cancer includes a description of current screening, diagnosis, and treatment options for localized prostate cancer. Educational resources appropriate for at-risk patients are outlined. - Linda H. Yoder, PhD, MBA, RN, AOCN(R), FAAN Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death among American males (Terris & Rhee, 2006). The incidence of this disease...

2008-09-25 09:00:54

LYON, France, Sept. 25, 2008 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its High Intensity Focused Ultrasound (HIFU) technology was highlighted at the City of Hope Second Annual Conference on New Technologies and Innovative Treatment Strategies for Genitourinary Malignancies from September 12-14, 2008 in San Diego, California. Douglas Chinn, MD of Chinn & Chinn Urology Medical Associates in Arcadia, California,...

2008-09-11 09:00:09

LYON, France, Sept. 11, 2008 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today its schedule to participate in national and local patient outreach efforts during prostate cancer awareness month. The Company hopes to increase its visibility among the prostate cancer patient and physician community as the leader in non-invasive therapeutic ultrasound. EDAP's presence is also aimed at accelerating recruitment efforts for patient enrollment...

2008-09-10 09:00:09

LYON, France, Sept. 10, 2008 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the launch of initial HIFU services at Amphia Ziekenhis Hospital, in Breda, the first Ablatherm robotic HIFU treatment center in the Netherlands. Dr. Harald Janssen, Head of the Urology Deptartment at Amphia Ziekenhis Hospital, in Breda, Netherlands, commented, "The Ablatherm device will enable our center to be at the forefront of the treatment of prostate...

2008-07-17 09:01:20

LYON, France, July 17, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that urologists at the University of Texas M.D. Anderson Cancer Center have treated their first two localized prostate cancer patients with Ablatherm-HIFU (high intensity focused ultrasound). The prestigious center is one of 13 Ablatherm sites participating in ENLIGHT, EDAP's ongoing Phase II/III clinical trial to evaluate the minimally invasive, robotized...

2008-07-03 09:00:00

LYON, France, July 3, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today it has entered into two new revenue per procedure (RPP) contracts in Germany with St. Barbara Hospital in Gladbeck and the Urological Clinic of the University of Heidelberg. EDAP recently entered into a new RPP contract with St. Barbara Hospital in Gladbeck. The Center has a history of commitment to exceptional patient care and cutting-edge research for the...

2006-03-27 15:25:00

By Karla Gale NEW YORK (Reuters Health) - When it comes to treating localized prostate cancer, treatment decisions frequently do not appear to reflect patient preferences, investigators report in an upcoming issue of Cancer. "I think fear is a big factor, and I don't think patients have the information to discriminate between what it means to have prostate cancer versus what it means to have other types of cancer that are more aggressive," Dr. Steven B. Zeliadt told Reuters Health. There is...

2006-02-14 13:24:40

NEW YORK (Reuters Health) - The time elapsed between a diagnosis of localized prostate cancer and surgery does not appear to have a large effect on the risk of cancer recurrence, according to a study. However, doctors say it's best to avoid undue delays. Men diagnosed with localized prostate cancer must educate themselves about the disease and the available treatment options. This can take time, often leading to delays in treatment. Waiting lists for surgery may also delay...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related